RE:FYIMelnykWasRight wrote:
Natesto manufacturing/dispenser issue has been resolved and is awaiting anticipated Health Canada approval in very near future. Replacement inventory is ready to go. More positive news hopefully prior to next quarterly report. There's light at the end of the tunnel and that light may not be the freight train we were expecting after all. ;)
MelnykWasNotWrong...
If this was the case, shouldn't the company put up a NR to that effect?
Natesto now has tremendous potential but there are 3 - 4 questions plaguing this Company in the very short term.
Have they fixed the ST Manufacturing problem ?
How much damage was done as a result in the last Qtr ?
Solvency. Can they hang on until Sales pick up substantially, and they become CF positive?
Will the owners dig into their own pockets once again if they become insolvent?
If Urologists are doing their job properly, about 50% of current Testosterone users will/should reconsider the brand they use. There is no saying how many will switch to natesto...as for a good percentage of them, it will be too late to switch anyway. And or, many may decide to remain brand loyal despite the confirmed advantages now offered by Natesto.
Going forward, it stands to reason that a much higher percentage of NEW Testosterone user perscriptions will be written for Natesto (especially for those men under the age of 50). That is almost a given. While very positive, higher market share for new users is not the same as an immediate change in market share for existing users.
My assessment is that if both companies can somehow hold on, there is enough potential for Ascerus and AYTU to make a lot of money in the future, ....IF... they can hold on.
MM